Background
This phase II trial was designed to evaluate the benefit of Keytruda® plus Zolinza® for recurrent Head and Neck Squamous Cell Carcinoma, HNSCC and Salivary Gland Cancer, SGC.
Among patients with HNSCC, there were no complete remissions but 32% of patients experienced a partial response and a further 20% had stable disease.
16% of patients with salivary gland cancer experienced a partial response while 56% had stable disease.
Results
25 HNSCC and 25 SGC patients were enrolled to the study. The most common adverse events were renal insufficiency, fatigue and nausea. There were 3 deaths on study.
Responses to the two drug combination in HN were: partial response in 32% of patients, stable disease in 20% of patients.
Efficacy in SGC: Partial response in 16% of patients and disease stabilization in 56% of patients. In the HNSCC group, median overall survival was 12.6 months and median time until disease progression was 4.5 months. In SGC, the median overall survival was 14.0 months, and median time until disease progression was 6.9 months.
Conclusion
This combination demonstrated activity in HNSCC, with fewer responses in SGC. Toxicities were higher than reported with Keytruda® alone.
Notes
- Zolinza® is approved for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)
- Keytruda® is approved for across a broad range of cancers, such as Renal cell cancer, Lung cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Gastric cancer and many others.
The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.
Contact us to find out what is the best treatment for YOU
TRIAL•IN Pharma
Do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039
